FIELD: medicine; endocrinology; nephrology.
SUBSTANCE: present group of invention concerns treating diabetic nephropathy. That is ensured by administering an effective amount of a compound inhibiting the VEGF-B signaling pathway.
EFFECT: provides effective correction of renal function by selective binding of VEGF-B inhibitor with VEGFR-2 receptor.
10 cl, 35 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OR PREVENTION OF STROKE | 2015 |
|
RU2744909C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2019 |
|
RU2747735C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| ANTI-MET ANTIBODIES AND THEIR USE | 2017 |
|
RU2765267C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES, CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TISSUE-PENETRATING PEPTIDE AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED | 2016 |
|
RU2712623C2 |
| ANTIBODY AGAINST ANG2 AND ITS USE | 2020 |
|
RU2788088C1 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2743409C2 |
